A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
Clinical trial NCT06211764 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06211764
- Sponsor
- Janssen Research & Development, LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-04-09
- Primary completion
- 2030-11-27
- Enrollment
- 272
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.